Avadel Pharmaceuticals
- Country
- 🇮🇪Ireland
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 154
- Market Cap
- $1.5B
- Website
- http://www.avadel.com
- Introduction
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals Appoints Susan Rodriguez as Chief Operating Officer to Drive LUMRYZ Commercial Expansion
Avadel Pharmaceuticals has appointed Susan Rodriguez as Chief Operating Officer to lead commercial strategy and operations for LUMRYZ, the first once-at-bedtime oxybate treatment for narcolepsy.
Vivo Capital Secures $740 Million for Third Cycle of Healthcare Investment Fund
Vivo Capital has closed the third cycle of its Opportunity Fund with over $740 million in commitments, focusing on preclinical and clinical-stage life sciences companies developing novel therapies.
Avadel Wins Federal Circuit Appeal: Path Cleared for LUMRYZ Development in Idiopathic Hypersomnia
The U.S. Court of Appeals for the Federal Circuit has overturned key portions of a Delaware Court injunction, allowing Avadel Pharmaceuticals to seek FDA approval for LUMRYZ in idiopathic hypersomnia.
Once-Nightly Sodium Oxybate Shows Safety Profile in Narcolepsy Patients with Sleep Apnea Concerns
Post-hoc analysis of the phase 3 REST-ON trial demonstrates that once-nightly sodium oxybate (Lumryz) does not worsen apnea-hypopnea index in narcolepsy patients with mild or no sleep apnea.
Hypersomnia Pipeline Shows Promise with 10+ Emerging Therapies in Development
DelveInsight's latest report reveals 8+ companies developing 10+ therapies for hypersomnia, with Avadel's Lumryz, Zevra's KP1077, and Alkermes' ALKS 2680 among the key candidates advancing through clinical trials.
FDA Grants Orphan Drug Exclusivity to LUMRYZ for Narcolepsy Treatment, Marking First Once-Nightly Oxybate Therapy
The FDA has approved LUMRYZ as the first and only once-nightly oxybate treatment for narcolepsy, supported by successful Phase 3 REST-ON trial results showing significant improvements in excessive daytime sleepiness and cataplexy.
Avadel Pharmaceuticals Announces Strong LUMRYZ Growth and Outlines 2025 Priorities
Avadel Pharmaceuticals reports a significant increase in LUMRYZ revenue, with Q4 2024 sales estimated at $50 million, a 150% increase from Q4 2023.
Avadel Pharmaceuticals' LUMRYZ Shows Strong Growth and Receives Expanded FDA Approval
Avadel Pharmaceuticals reported $50.0 million in net revenue from LUMRYZ sales in Q3 2024, marking substantial growth in the narcolepsy treatment market.
Court Upholds FDA Approval of Avadel's Lumryz for Narcolepsy, Dismissing Jazz Pharma's Challenge
A US court has ruled in favor of the FDA, upholding the approval of Avadel Pharmaceuticals' Lumryz for treating narcolepsy.
Court Upholds FDA Approval of Avadel's Once-Nightly Narcolepsy Drug LUMRYZ
A U.S. District Court affirmed the FDA's approval of Avadel's LUMRYZ, a once-at-bedtime oxybate treatment for narcolepsy, supporting its clinical superiority over twice-nightly options.